Iain A McNeish

Publications

• Weekly Dose-dense Chemotherapy in First-line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results from a GCIG Phase 3 Randomised Controlled Trial
  Lancet (London, England). Nov, 2019  |   Pubmed ID: 31791688
• Prophylactic in Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models
  Cancer Research. Nov, 2019  |   Pubmed ID: 31727629
• Antitumor Activity of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib As Monotherapy in Patients with Platinum-sensitive, Relapsed, -mutated, High-grade Ovarian Cancer, and an Update on Safety
  International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. Nov, 2019  |   Pubmed ID: 31685558
• Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
  Cells. 02, 2019  |   Pubmed ID: 30813545
• Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
  Cancer Research. 02, 2019  |   Pubmed ID: 30559148
• Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
  Cancer Discovery. 02, 2019  |   Pubmed ID: 30425037
• Mannose Impairs Tumour Growth and Enhances Chemotherapy
  Nature. 11, 2018  |   Pubmed ID: 30464341
• Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian Carcinoma
  Nature Communications. 09, 2018  |   Pubmed ID: 30266954
• Rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology
  International Journal of Molecular Sciences. Aug, 2018  |   Pubmed ID: 30134598
• Copy Number Signatures and Mutational Processes in Ovarian Carcinoma
  Nature Genetics. 09, 2018  |   Pubmed ID: 30104763
• A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
  Cancer Research. 09, 2018  |   Pubmed ID: 30054336
• Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 11, 2018  |   Pubmed ID: 29980529
• Author Correction: CRISPR/Cas9-derived Models of Ovarian High Grade Serous Carcinoma Targeting Brca1, Pten and Nf1, and Correlation with Platinum Sensitivity
  Scientific Reports. Apr, 2018  |   Pubmed ID: 29651149
• RIPK3 Promotes Adenovirus Type 5 Activity
  Cell Death & Disease. 12, 2017  |   Pubmed ID: 29238045
• CRISPR/Cas9-derived Models of Ovarian High Grade Serous Carcinoma Targeting Brca1, Pten and Nf1, and Correlation with Platinum Sensitivity
  Scientific Reports. 12, 2017  |   Pubmed ID: 29203787
• Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd Edition)
  Autophagy. Jan, 2016  |   Pubmed ID: 26799652
• Rethinking Ovarian Cancer II: Reducing Mortality from High-grade Serous Ovarian Cancer
  Nature Reviews. Cancer. Nov, 2015  |   Pubmed ID: 26493647
• Repeatability of Quantitative FDG-PET/CT and Contrast-enhanced CT in Recurrent Ovarian Carcinoma: Test-retest Measurements for Tumor FDG Uptake, Diameter, and Volume
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2014  |   Pubmed ID: 24573555
• Rethinking Ovarian Cancer: Recommendations for Improving Outcomes
  Nature Reviews. Cancer. Oct, 2011  |   Pubmed ID: 21941283
• Fibroblast Growth Factor 2-mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells
  Molecular and Cellular Biology. Nov, 2003  |   Pubmed ID: 14560006